CompletedNot Applicable

Cross-linked CMC and Silk Proteins in Corneal Re-epithelization

Italy20 participantsStarted 2023-01-01

Plain-language summary

Data analyses and revision of the corneal re-epithelization in patients who underwent either PRK (Photorefractive Keratectomy), CXL (Corneal Cross-Linking), PTK (phototherapeutic keratectomy), or experienced a corneal abrasion. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market. Both molecules have been widely studied for their wound healing properties in the ophtalmic field. This new ophthalmic solution is the first on the market formulated with a CX-CMC and SP.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who had undergone surgical procedures involving de-epithelialization, which included CXL, PRK, and PTK, as well as those with a first diagnosis of corneal abrasion Exclusion Criteria: * patients with known allergies or hypersensitivity to any components of the tested formulations or standard therapies, or those requiring different treatments compared to the rest of the study population

What they're measuring

Corneal re-ephitalization

Timeframe: 2 WEEKS

Trial details

NCT IDNCT06840990

SponsorD&V FARMA srl

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-05-01

View on ClinicalTrials.gov More Corneal Epithelial Wound Healing trials